The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia

G. K. Schleicher, C. Feldman, A. Brink, J. S. Galpin, S. Martin, R. Maraj (Johannesburg, South Africa)

Source: Annual Congress 2004 - SARS and other lower respiratory tract infections

Session: SARS and other lower respiratory tract infections
Session type: Poster Discussion
Number: 1577

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. K. Schleicher, C. Feldman, A. Brink, J. S. Galpin, S. Martin, R. Maraj (Johannesburg, South Africa). The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia. Eur Respir J 2004; 24: Suppl. 48, 1577

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia Source: Eur Respir J 2005; 25: 688-692 Year: 2005
Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012
Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011
C-reactive protein (CRP), an early prognostic tool in community acquired pneumonia (CAP) Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009
Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010
Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007
C Reactive Protein (CRP), procalcitonin (PCT) and proadrenomedullin (Pro-ADM), as markers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007
Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia? Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011
Diagnostic accuracy of lipopolysaccharide-binding protein (LBP), fibrinogen and C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014